Parkinson's Disease Psychosis: A Pharmacist's Update of New Treatment Options
This Continuing Education activity is supported by an educational grant from Acadia Pharmaceuticals Inc.
This activity is supported by an educational grant from Acadia Pharmaceuticals Inc.
Jack J. Chen, PharmD, BCPS, BCGP, FASCP, FCCP
Department of Pharmacy Practice College of Pharmacy
Marshall B. Ketchum University Fullerton, California
Movement Disorders Center Department of Neurology Loma Linda, California
After completing this continuing education program, the participant will be able to:
- Identify the clinical features and risk factors of Parkinson’s disease psychosis (PDP)
- Differentiate the pharmacology, safety, and efficacy of available pharmacologic treatment options for PDP
- Explore optimal management strategies for patients with PDP
Target audience: Pharmacists
Type of activity: Application
Release date: December 12, 2016
Expiration date: December 12, 2017
Estimated time to complete activity: 2.0 hours
Pharmacy Times Continuing Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEUs) under the ACPE universal activity number 0290-0000-16-152-H01-P. The activity is available for CE credit through December 12, 2017.